Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Protara Therapeutics (TARA – Research Report). The associated price target remains the same with $22.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Charles Zhu has given his Buy rating due to a combination of factors including Protara Therapeutics’ recent updates and promising clinical data. The company has reported positive interim results from its ADVANCED-2 study, showing significant complete response rates in patients with non-muscle invasive bladder cancer (NMIBC), which highlights the potential efficacy of their TARA-002 treatment. Additionally, the management’s guidance on upcoming milestones, such as the expected interim data for BCG-unresponsive patients and the initiation of patient dosing for the THRIVE-3 study, indicates a clear path forward in their clinical development.
Furthermore, Protara’s strong financial position, with $158 million in cash and equivalents, provides a solid foundation to support its planned activities. Despite macroeconomic challenges affecting some shareholders, the company remains confident in its differentiated mechanism of action and its ability to compete in the NMIBC market. The lack of delays in FDA discussions and the proactive approach towards regulatory engagements further reinforce the positive outlook for Protara Therapeutics, justifying the Buy rating.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $23.00 price target.